BDR Pharmaceuticals announces license agreement with DRDO for manufacturing Covid-19 Drug 2-DG in India

26-07-2021 Mon 11:35

Mumbai, 26 July 2021: BDR Pharma, one of India's leading generic pharmaceutical companies, has received an approval and signed a license agreement with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the Defence Research and Development Organisation (DRDO) for the manufacturing, distribution, and marketing of 2- Deoxy-D-Glucose (2-DG) in India. Last month, the Drugs Controller General of India (DCGI) approved the oral medication for emergency usage as adjuvant therapy in mild to severe Covid-19 patients.
The Defence Research and Development Establishment (DRDE) in Gwalior had produced 2-DG. The clinical trials were carried out in collaboration with Dr. Reddy's Laboratories by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a DRDO lab. After receiving positive responses in Phase-II and Phase-IIb trials, DCGI permitted 2DG phase-III trials in November 2020. The Phase-II trial, which lasted from December 2020 to March 2021, enrolled 220 patients. The medicine was discovered to speed up the recovery of COVID-19 patients in hospitals and to lessen the need for supplementary oxygen in COVID-19 patients.
Commenting on the development Mr. Dharmesh Shah, CMD, BDR Pharmaceuticals, expressed, "We are pleased to secure a license from the DRDO and add 2-Deoxy-D-Glucose to our Covid product offering. This arrangement aims to ensure that this drug reaches as many eligible Indian patients as possible who are suffering from the devastating pandemic. Our aim is to ramp up the availability of successful treatment and coordinate manufacturing so that there is no scarcity of drugs to give to people fighting the disease. We expect that by widening and deepening the identification and development of COVID-19 therapy options, this collaboration can address more unmet medical needs."
This collaboration will improve local treatment options and positively impact the lives of COVID-19 patients in India. Clinical trial data supplied by the government based on the emergency approval demonstrated that the chemical aids in the speedier recovery of Covid-19 patients and minimizes their reliance on supplementary oxygen. In addition, the medication builds up in virus-infected cells and stops viral manufacturing and energy production, preventing the virus from spreading.
The product will be priced competitively and will be available in powder form in a sachet that can be consumed orally after being dissolved in water.
BDR has applied to the Drug Controller General of India (DCGI) for restricted emergency use authorization to manufacture Drug 2-DG to treat COVID-19 patients in India. For the development of 2-DG drugs, the DRDO has recently signed agreements with four major Indian generic medicine producers.

More Press Releases
Governor Tamilisai performs Ayudha Puja at Raj Bhavan
PM prays for speedy recovery of Manmohan Singh
సద్దుల బతుకమ్మ శుభాకాంక్షలు తెలిపిన సీఎం కేసీఆర్
సద్దుల బతుకమ్మ సంబురాల్లో పాల్గొన్న సీఎం కేసీఆర్ సతీమణి శోభమ్మ
Central Govt MEE team visits Telangana
Prime Minister launches PM Gati Shakti
వైఎస్ఆర్ ఆసరా పథకం ద్వారా డ్వాక్రా సంఘాలకు రెండవ విడతగా బ్యాంక్ లలో నగదు జమ
Reliance new energy solar ltd and Denmark’s Stiesdal A/S sign a cooperation agreement
Union Bank of India signs MoU with CDAC, Hyderabad
వరి వేసినా ఉరే.. వరి తిన్నా ఉరే: మంత్రి జగదీష్ రెడ్డి
వీధులను పాదచారులకు అనువుగా, ఆహ్లాదకరంగా తీర్చిదిద్దడమే లక్ష్యంగా స్ట్రీట్ ఫర్ పీపుల్: వైసీపీ ఎమ్మెల్యే మల్లాది విష్ణు
Paytm brings Digilocker to its Mini App Store - now access all your documents digitally
కోవిడ్ మెగా వ్యాక్సిన్ కేంద్రాన్ని ప్రారంభించిన తెలంగాణ సీఎస్ సోమేశ్ కుమార్
మహిళలకు అధిక ప్రాధాన్యత కల్పించిన ఏకైక ప్రభుత్వం వైఎస్ఆర్సీపీ: విజయవాడ మేయర్ రాయన భాగ్యలక్ష్మి
HP introduces first AMD-powered Chromebook PCs for digital learners